Alnylam Pharmaceuticals, Inc. (ALNY) PT Raised to $128.00
Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) had its target price increased by JMP Securities from $101.00 to $128.00 in a research report released on Wednesday morning. The firm currently has an outperform rating on the biopharmaceutical company’s stock.
Several other research firms have also recently weighed in on ALNY. Cowen and Company restated a buy rating and issued a $100.00 price target on shares of Alnylam Pharmaceuticals in a research note on Tuesday, July 11th. Jefferies Group LLC set a $102.00 price target on Alnylam Pharmaceuticals and gave the stock a buy rating in a research note on Friday, August 25th. Barclays PLC boosted their price target on Alnylam Pharmaceuticals from $50.00 to $70.00 and gave the stock an equal weight rating in a research note on Thursday, August 10th. Credit Suisse Group boosted their price target on Alnylam Pharmaceuticals from $90.00 to $96.00 and gave the stock an outperform rating in a research note on Tuesday, June 27th. Finally, BMO Capital Markets restated an outperform rating and issued a $99.00 price target (down previously from $105.00) on shares of Alnylam Pharmaceuticals in a research note on Wednesday, September 6th. Three investment analysts have rated the stock with a sell rating, eight have assigned a hold rating and fourteen have given a buy rating to the company’s stock. The company presently has an average rating of Hold and a consensus price target of $93.11.
Alnylam Pharmaceuticals (NASDAQ:ALNY) opened at 113.80 on Wednesday. The company’s market cap is $10.44 billion. Alnylam Pharmaceuticals has a 52 week low of $31.38 and a 52 week high of $118.40. The firm has a 50-day moving average price of $81.14 and a 200-day moving average price of $69.12.
Alnylam Pharmaceuticals (NASDAQ:ALNY) last posted its quarterly earnings results on Wednesday, August 9th. The biopharmaceutical company reported ($1.34) earnings per share for the quarter, missing the Thomson Reuters’ consensus estimate of ($1.22) by ($0.12). Alnylam Pharmaceuticals had a negative return on equity of 45.53% and a negative net margin of 670.81%. The business had revenue of $15.93 million during the quarter, compared to analysts’ expectations of $23.86 million. During the same quarter in the prior year, the firm earned ($1.05) EPS. The firm’s revenue for the quarter was up 82.9% compared to the same quarter last year. Equities research analysts anticipate that Alnylam Pharmaceuticals will post ($5.19) EPS for the current fiscal year.
TRADEMARK VIOLATION WARNING: “Alnylam Pharmaceuticals, Inc. (ALNY) PT Raised to $128.00” was originally reported by Daily Political and is the property of of Daily Political. If you are reading this news story on another site, it was illegally stolen and republished in violation of United States and international trademark and copyright legislation. The original version of this news story can be read at https://www.dailypolitical.com/2017/09/24/alnylam-pharmaceuticals-inc-alny-pt-raised-to-128-00.html.
In other Alnylam Pharmaceuticals news, President Barry E. Greene sold 76,815 shares of the business’s stock in a transaction dated Wednesday, September 20th. The stock was sold at an average price of $100.00, for a total transaction of $7,681,500.00. Following the completion of the sale, the president now owns 165,399 shares of the company’s stock, valued at $16,539,900. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through the SEC website. Insiders own 4.30% of the company’s stock.
Large investors have recently added to or reduced their stakes in the business. QS Investors LLC grew its holdings in Alnylam Pharmaceuticals by 59.7% during the second quarter. QS Investors LLC now owns 2,408 shares of the biopharmaceutical company’s stock valued at $192,000 after purchasing an additional 900 shares during the period. The Manufacturers Life Insurance Company boosted its stake in shares of Alnylam Pharmaceuticals by 7.0% in the second quarter. The Manufacturers Life Insurance Company now owns 2,541 shares of the biopharmaceutical company’s stock worth $203,000 after acquiring an additional 167 shares during the period. CIBC Asset Management Inc bought a new position in shares of Alnylam Pharmaceuticals in the second quarter worth about $221,000. Neuberger Berman Group LLC bought a new position in shares of Alnylam Pharmaceuticals in the second quarter worth about $229,000. Finally, Zurcher Kantonalbank Zurich Cantonalbank bought a new position in shares of Alnylam Pharmaceuticals in the first quarter worth about $148,000. 94.25% of the stock is owned by institutional investors and hedge funds.
About Alnylam Pharmaceuticals
Alnylam Pharmaceuticals, Inc is a biopharmaceutical company. The Company is engaged in the discovery, development and commercialization of ribonucleic acid (RNA) interference (RNAi) therapeutics. The Company is focused on the use of its N-acetylgalactosamine (GalNAc)-conjugate platform for delivery of small interfering RNAs (siRNAs).
Receive News & Ratings for Alnylam Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Alnylam Pharmaceuticals Inc. and related companies with MarketBeat.com's FREE daily email newsletter.